Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 3/20 | 0.61 |
| ▸ | JAK1 | P23458 | 3/20 | 0.57 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.53 |
| ▸ | JAK3 | P52333 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 8/20 | 0.45 |
| ▸ | GRK5 | P34947 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.39 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19659225 | 0.84 | EGLN2 (0.55) | NUDT1JAK1EGLN2FYNGRK5 | |
| SCHEMBL18366732 | 0.83 | FYN (0.45) | NUDT1JAK1EGLN2FYNGRK5 | |
| SCHEMBL3587361 | 0.83 | NUDT1 (0.55) | NUDT1JAK1EGLN2JAK3JAK2 | |
| SCHEMBL19658699 | 0.81 | GRM2 (0.44) | NUDT1JAK1FYNGRK5LCK | |
| SCHEMBL15268998 | 0.81 | FYN (0.46) | NUDT1FYNGRK5CHEK1 | |
| SCHEMBL18366726 | 0.80 | CHEK1 (0.43) | NUDT1JAK1FYNGRK5CHEK1 | |
| SCHEMBL3210559 | 0.79 | JAK2 (0.58) | NUDT1JAK1EGLN2JAK3JAK2 | |
| SCHEMBL3597676 | 0.78 | NUDT1 (0.52) | NUDT1JAK1EGLN2JAK3JAK2 | |
| SCHEMBL2144054 | 0.77 | NUDT1 (1.00) | NUDT1JAK1EGLN2JAK3GRK5 | |
| SCHEMBL18366724 | 0.77 | FYN (0.43) | JAK1JAK3FYNJAK2LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889673-B2 | Triazolopyridine JAK inhibitor compounds and methods | GENENTECH, INC. (US) | 2014-11-18 | — | — | US | claimed |
| US-12281101-B2 | Bicyclic lactams and methods of use thereof | GENENTECH, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| EP-3760625-B1 | BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES | HOFFMANN LA ROCHE (CH) | 2024-03-27 | — | — | EP | disclosed |
| CN-111269221-B | Bicyclic lactams and methods of use thereof | 豪夫迈·罗氏有限公司 | 2023-09-26 | — | — | CN | disclosed |
| US-20220348559-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-11-03 | — | — | US | disclosed |
| EP-3317269-B1 | BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES | HOFFMANN LA ROCHE (CH) | 2022-09-21 | — | — | EP | disclosed |
| CN-112979660-A | Bicyclic lactams and methods of use thereof | 豪夫迈·罗氏有限公司 | 2021-06-18 | — | — | CN | disclosed |
| US-10988459-B2 | Bicyclic lactams and methods of use thereof | GENENTECH, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-10988459-B2 | Bicyclic lactams and methods of use thereof | GENENTECH, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| CN-107849023-B | Bicyclic lactams and methods of use thereof | 豪夫迈·罗氏有限公司 | 2021-03-23 | — | — | CN | disclosed |
| US-8889673-B2 | Triazolopyridine JAK inhibitor compounds and methods | GENENTECH, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889673-B2 | Triazolopyridine JAK inhibitor compounds and methods | GENENTECH, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889673-B2 | Triazolopyridine JAK inhibitor compounds and methods | GENENTECH, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20120264747-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | ZHU BING-YAN (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120264747-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | ZHU BING-YAN (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120264747-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | ZHU BING-YAN (US) | 2012-10-18 | — | — | US | disclosed |
| US-20100035875-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. | 2010-02-11 | — | — | US | disclosed |
| US-20100035875-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. | 2010-02-11 | — | — | US | disclosed |
| US-20100035875-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. | 2010-02-11 | — | — | US | disclosed |
| WO-2009155565-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220348559-A1 | BICYCLIC LACTAMS AND METHODS OF USE THEREOF | LSS, LPXN, CYP1B1 | NUDT1 2795/4885JAK1 3884/4885EGLN2 2075/4885 |
| US-10988459-B2 | Bicyclic lactams and methods of use thereof | LSS, LPXN, CYP1B1 | NUDT1 2795/4885JAK1 3884/4885EGLN2 2075/4885 |
| US-12281101-B2 | Bicyclic lactams and methods of use thereof | LSS, LPXN, CYP1B1 | NUDT1 2795/4885JAK1 3884/4885EGLN2 2075/4885 |
| US-20120264747-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | NUDT1 3080/4885JAK1 2/4885EGLN2 3771/4885 |
| US-20100035875-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | NUDT1 3080/4885JAK1 2/4885EGLN2 3771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.